[Toxicity and hematopoietic regeneration produced by adjuvant chemotherapy in patients with neoplasia of the breast].
Benet
I
I
Peñarroja
C
C
Ubeda
F
F
Lluch
A
A
Carbonell
F
F
Aguilar
N
N
Alberola
V
V
García-Conde
J
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D001855:Bone Marrow Diseases / Q000097:blood / Q000139:chemically induced*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003114:Colony-Forming Units Assay; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged
D004317:Doxorubicin; D008727:Methotrexate
Estudio de la toxicidad y de la regeneración hematopoyética producida por la quimioterapia adjuvante en pacientes con neoplasia de mama.